Skip to main content
. 2015 Feb 25;67(3):668–677. doi: 10.1002/art.38973

Figure 2.

Figure 2

Mean Ankylosing Spondylitis Disease Activity Score (ASDAS) (A), percentage of patients in whom ASDAS major improvement was achieved (B), and percentage of patients with ASDAS inactive disease (C) to week 96 of certolizumab pegol (CZP) treatment in patients with axial spondyloarthritis (axSpA), patients with AS, and patients with nonradiographic axial SpA. Graphs show last observation carried forward (LOCF) data. Results are reported for the randomized set (all patients randomized at baseline to receive either CZP 200 mg every 2 weeks or CZP 400 mg every 4 weeks). 96 (OC) = observed case data for week 96 (n = 171 patients with axial SpA; n = 97 patients with AS; n = 74 patients with nonradiographic axial SpA).